Latest filing published 10 Jan 2023 for Sun Pharma Advanced Research Company Limited, €38.8M.
Insider track record
Dilip Shantilal Shanghvi: trading record in brief
Dilip Shantilal Shanghvi, listed as chief executive, appears in our data through filings on Sun Pharma Advanced Research Company Limited shares, published by SEBI (PIT + SAST). We count 5 filings; the first trade dates from 8 July 2021 and the latest from 6 January 2023.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
The record was last updated on 10 January 2023 with a transaction (€38.8M) in Sun Pharma Advanced Research Company Limited. The median gap between a trade and its publication by SEBI (PIT + SAST) is 2 days. This delay matters because a trade only becomes useful information once it is public. These figures are compiled from regulatory filings published by SEBI (PIT + SAST). They describe what insiders did and are not a recommendation.
Companies and markets linked to Dilip Shantilal Shanghvi
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 25,280,899 shares@ ₹133.5056.2% of flowEquity SharesSEBI:281cdbaee9aa31e4f1f495d58e3b6d3b61469584
- 25,280,899 sharesWarrantsSEBI:717d1c21621b5659fd48f449281d056c402d2c29
- 8,426,966 shares@ ₹133.5019.3% of flowEquity SharesSEBI:785977ad4583f1d47711324b3907b344d060f820
- 8,426,966 sharesWarrantsSEBI:9d89002c7269e982fe9495442694bb03b8205ec7
- 33,707,865 shares@ ₹44.5024.5% of flowWarrantsSEBI:7bd64a2dda8a9ab710dda4b7cbcfec9000131d34
5 of 5 declarations